BWA
IRWD icon

Basecamp Wealth Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Basecamp Wealth Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.28K Sell
542
-54
-9% -$208 ﹤0.01% 1340
2026
Q1 		$2.09K Buy
+596
New +$2.44K ﹤0.01% 1386

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Basecamp Wealth Advisors's IRWD Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its Ironwood Pharmaceuticals (IRWD) stake by 9.1% in Q2 2026, selling an estimated $208 and leaving 542 shares worth $2.28K. The position accounts for ﹤0.01% of the portfolio, ranked #1340.

Basecamp Wealth Advisors first reported a position in IRWD in Q1 2026 and has held it in 2 quarters since. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Basecamp Wealth Advisors held 542 shares of Ironwood Pharmaceuticals worth $2.28K as of Q2 2026.
  • Basecamp Wealth Advisors sold 54 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $208.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1340 holding.
  • Basecamp Wealth Advisors first reported a position in Ironwood Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.